FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
38 letters match. Newest first.
-
DrugsNanjing Hanxin Pharmaceutical Technology Co. Ltd.
FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.
High risk -
DrugsRonanRx, Inc. dba RonanRx
FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
High risk -
DrugsTianjin Kilo Pharmaceutical Sci-tech Co., Ltd.
Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.
High risk -
DrugsKetamine Troche Store / www.ketaminetrochestore.com
FDA warned online seller Ketamine Troche Store that its website sells unapproved, misbranded ketamine drugs without prescriptions.
High risk -
DrugsBuy Keta Online / www.buyketaonline.com
FDA warns Buy Keta Online that its website sells unapproved and misbranded ketamine drugs to U.S. consumers.
High risk -
DrugsKetamine Store / www.ketaminestore.org
FDA warned website Ketamine Store for selling unapproved, misbranded ketamine liquid and compounded products online without prescriptions.
High risk -
DrugsNativeMed LLC dba NativeMed
FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsNexus Health Solutions LLC dba Harper Meds
FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Low -
DrugsGlow Medispa, LLC dba Mint Med
FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.
Low -
DrugsD&H Medical Services
FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.
Low -
DrugsMedica Weight Loss
FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.
Medium -
DrugsOrderlyMeds LLC dba OrderlyMeds
FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.
Low -
DrugsJoi and Blokes dba Joi + Blokes
FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.
Medium -
DrugsClover Meds LLC dba Clover Meds
Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.
Medium -
DrugsRefills Health, LLC dba Refills Health
FDA told telehealth seller Refills Health its website misbrands compounded semaglutide by implying FDA approval and naming itself as maker.
Medium -
DrugsWeightless Medical LLC dba WeightCare
FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.
Low -
DrugsViv Health, Inc. dba VIV RX
FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsIvim Services LLC dba Ivim
FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.
Low -
DrugsMaxLife Technologies Inc. dba Maxlife
FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.
Medium -
DrugsBetter Health Labs, Inc. dba Measured
FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.
Medium -
DrugsMEDVi, LLC dba MEDVi
FDA says telehealth seller MEDVi misbranded compounded semaglutide and tirzepatide by implying MEDVi makes them and that they are FDA-approved.
Medium -
DrugsNewman Clinic, PLLC dba Newman Clinic
FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsBliv Wellness LLC dba Bliv
FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.
Medium -
DrugsDarmerica, LLC
FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.
High risk -
DrugsAmazing Meds
FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
High risk -
DrugsGenLabMeds
GenLabMeds offered compounded retatrutide, semaglutide and tirzepatide online as unapproved, misbranded drugs with false or misleading claims.
High risk -
DrugsMedClub by Dr. Jenn
FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
High risk -
DrugsGLP-1 Solution
GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.
High risk -
DrugsASN-LABS
ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.
High risk -
DrugsEA WORKS Limited Liability Company dba Trust Labs
FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.
High risk -
DrugsSouthern Tier Home Infusion, Inc. dba Pharmacy Innovations
FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.
High risk -
DrugsCarolina Infusion
FDA warns Carolina Infusion over compounded drugs made without valid prescriptions and under insanitary conditions, including sterile products.
High risk -
DrugsBelmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy
FDA warns Drug Depot dba APS Pharmacy over compounded drugs made with ineligible bulk substances.
Medium -
DrugsAdvanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine
Advanced Nutriceuticals compounded sterile drugs without required prescriptions and under insanitary conditions, FDA says.
High risk -
DrugsMatthew 7:25 Inc dba Thrive Pharmacy
FDA says Thrive Pharmacy compounded drugs without valid prescriptions and released subpotent buprenorphine troches, making them adulterated and misbranded.
High risk -
DrugsWalfer Corporation dba The Medicine Shoppe Pharmacy
FDA warned The Medicine Shoppe Pharmacy in Port Charlotte, Florida, over insanitary compounding conditions, vermin, and drugs made without valid prescriptions.
High risk -
DrugsPharmaceutical Care Solutions dba Pharmacy Solutions
FDA warns Pharmaceutical Care Solutions dba Pharmacy Solutions over compounded drugs made with ineligible bulk substances and lacking FDA approval.
Medium